Drug developer Moderna Inc on Friday said it has so far enrolled 13,194 participants in the ongoing late-stage 30,000-volunteer U.S. trial testing its COVID-19 vaccine candidate.
In a tweet, the company also said that 18% of the participants currently enrolled are Black, Latino, American Indian or Alaska Native, groups among the hardest hit by the coronavirus virus pandemic.
Last week, the company entered a supply agreement with the U.S. government to provide 100 million doses of its potential COVID-19 vaccine for around $1.5 billion.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Russia approves trial of AstraZeneca COVID-19 vaccine: registry filingBritain's AstraZeneca has received regulatory approval to conduct part of a Phase III trial of its potential COVID-19 vaccine in Russia, a filing in the Russian registry of clinical trials showed on Friday.
Weiterlesen »
Peru to test China Sinopharm's COVID-19 vaccine in Phase 3 trialHealth authorities of the Republic of Peru have approved a Phase 3 clinical trial for a potential COVID-19 vaccine developed by China National Biotec Group (CNBG), the company said on Thursday in Chinese social media platform Weibo.
Weiterlesen »
WSJ News Exclusive | For Covid-19 Vaccine, J&J Plans 60,000-Subject Pivotal TrialJohnson & Johnson plans to launch by late September what could become the largest clinical trial of a coronavirus vaccine to date, enlisting up to 60,000 people world-wide to test whether its experimental shot safely protects from Covid-19
Weiterlesen »
WSJ News Exclusive | Troubled Covid-19 Data System Returning to CDCThe U.S. Department of Health and Human Services is reversing course on a change to the way hospitals report critical information on the pandemic to the government, returning the responsibility for data collection to the Centers for Disease Control and Prevention.
Weiterlesen »